FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3011397103> ?p ?o ?g. }

• W3011397103 abstract "There are many health benefits since 31 years after the foundation of the National Health Service (NHS) in Brazil, especially the increase in life expectancy. However, family-income inequalities, insufficient funding, and suboptimal private sector-public sector collaboration are still areas for improvement. The efforts of Brazil to achieve universal health coverage (UHC) for medicines have resulted in increased public financing of medicines and their availability, reducing avoidable hospitalization and mortality. However, lack of access to medicines still remains. Due to historical reasons, pharmaceutical service organization in developing countries may have important differences from high-income countries. In some cases, developing countries finance and promote medicine access by using the public infrastructure of health care/medical units as dispensing sites and cover all costs of medicines dispensed. In contrast, many high-income countries use private community pharmacies and cover the costs of medicines dispensed plus a fee, which includes all logistic costs. In this study, we will undertake an economic evaluation to understand the funding needs of the Brazilian NHS to reduce inequalities in access to medicines through adopting a pharmaceutical service organization similar to that seen in many high-income countries with hiring/accrediting private pharmacies.We performed an economic evaluation of a model to provide access to medicines within public funds based on a decision tree model with two alternative scenarios public pharmacies (NHS, state-owned facilities) versus private pharmacies (NHS, agreements). The analysis assumed the perspective of the NHS. We identified the types of resources consumed, the amount, and costs in both scenarios. We also performed a budget impact forecast to estimate the incremental funding required to reduce inequalities in access to essential medicines in Brazil.The model without rebates for medicines estimated an incremental cost of US$3.1 billion in purchasing power parity (PPP) but with an increase in the average availability of medicines from 65% to 90% for citizens across the country irrespective of family income. This amount places the NHS in a very good position to negotiate extensive rebates without the need for external reference pricing for government purchases. Forecast scenarios above 35% rebates place the alternative of hiring private pharmacies as dominant. Higher rebate rates are feasible and may lead to savings of more than US$1.3 billion per year (30%). The impact of incremental funding is related to medicine access improvement of 25% in the second year when paying by dispensing fee. The estimate of the incremental budget in five years would be US$4.8 billion PPP. We have yet to explore the potential reduction in hospital and outpatient costs, as well as in lawsuits, with increased availability with the yearly expenses for these at US$9 billion and US$1.4 billion PPP respectively in 2017.The results of the economic evaluation demonstrate potential savings for the NHS and society. Achieving UHC for medicines reduces household expenses with health costs, health litigation, outpatient care, hospitalization, and mortality. An optimal private sector-public sector collaboration model with private community pharmacy accreditation is economically dominant with a feasible medicine price negotiation. The results show the potential to improve access to medicines by 25% for all income classes. This is most beneficial to the poorest families, whose medicines account for 76% of their total health expenses, with potential savings of lives and public resources." @default.
• W3011397103 created "2020-03-23" @default.
• W3011397103 creator A5021328012 @default.
• W3011397103 creator A5021673905 @default.
• W3011397103 creator A5021718286 @default.
• W3011397103 creator A5028480298 @default.
• W3011397103 creator A5067330259 @default.
• W3011397103 creator A5075513094 @default.
• W3011397103 creator A5084443733 @default.
• W3011397103 creator A5087893304 @default.
• W3011397103 date "2020-04-14" @default.
• W3011397103 modified "2023-09-30" @default.
• W3011397103 title "Funding and Service Organization to Achieve Universal Health Coverage for Medicines: An Economic Evaluation of the Best Investment and Service Organization for the Brazilian Scenario." @default.
• W3011397103 cites W1611067671 @default.
• W3011397103 cites W1745658487 @default.
• W3011397103 cites W1999724294 @default.
• W3011397103 cites W2054294193 @default.
• W3011397103 cites W2085823445 @default.
• W3011397103 cites W2099949073 @default.
• W3011397103 cites W2104115221 @default.
• W3011397103 cites W2111524839 @default.
• W3011397103 cites W2122047846 @default.
• W3011397103 cites W2128150090 @default.
• W3011397103 cites W2143401180 @default.
• W3011397103 cites W2151444904 @default.
• W3011397103 cites W2156657585 @default.
• W3011397103 cites W2157213528 @default.
• W3011397103 cites W2181990680 @default.
• W3011397103 cites W2411299786 @default.
• W3011397103 cites W2522147722 @default.
• W3011397103 cites W2559883726 @default.
• W3011397103 cites W2560829224 @default.
• W3011397103 cites W2570174586 @default.
• W3011397103 cites W2589168254 @default.
• W3011397103 cites W2610713831 @default.
• W3011397103 cites W2743658562 @default.
• W3011397103 cites W2746434642 @default.
• W3011397103 cites W2748143134 @default.
• W3011397103 cites W2751699775 @default.
• W3011397103 cites W2761198089 @default.
• W3011397103 cites W2762323838 @default.
• W3011397103 cites W2762791616 @default.
• W3011397103 cites W2763624049 @default.
• W3011397103 cites W2767006897 @default.
• W3011397103 cites W2778240369 @default.
• W3011397103 cites W2787322606 @default.
• W3011397103 cites W2788385076 @default.
• W3011397103 cites W2793020561 @default.
• W3011397103 cites W2804005679 @default.
• W3011397103 cites W2808910719 @default.
• W3011397103 cites W2884259275 @default.
• W3011397103 cites W2884486468 @default.
• W3011397103 cites W2884807614 @default.
• W3011397103 cites W2894674325 @default.
• W3011397103 cites W2899026268 @default.
• W3011397103 cites W2902129153 @default.
• W3011397103 cites W2930875443 @default.
• W3011397103 cites W2952637388 @default.
• W3011397103 cites W2984738731 @default.
• W3011397103 cites W4240121138 @default.
• W3011397103 doi "https://doi.org/10.3389/fphar.2020.00370" @default.
• W3011397103 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7175689" @default.
• W3011397103 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32351382" @default.
• W3011397103 hasPublicationYear "2020" @default.
• W3011397103 type Work @default.
• W3011397103 sameAs 3011397103 @default.
• W3011397103 citedByCount "3" @default.
• W3011397103 countsByYear W30113971032021 @default.
• W3011397103 countsByYear W30113971032023 @default.
• W3011397103 crossrefType "journal-article" @default.
• W3011397103 hasAuthorship W3011397103A5021328012 @default.
• W3011397103 hasAuthorship W3011397103A5021673905 @default.
• W3011397103 hasAuthorship W3011397103A5021718286 @default.
• W3011397103 hasAuthorship W3011397103A5028480298 @default.
• W3011397103 hasAuthorship W3011397103A5067330259 @default.
• W3011397103 hasAuthorship W3011397103A5075513094 @default.
• W3011397103 hasAuthorship W3011397103A5084443733 @default.
• W3011397103 hasAuthorship W3011397103A5087893304 @default.
• W3011397103 hasBestOaLocation W30113971031 @default.
• W3011397103 hasConcept C10138342 @default.
• W3011397103 hasConcept C104863432 @default.
• W3011397103 hasConcept C121426985 @default.
• W3011397103 hasConcept C133925201 @default.
• W3011397103 hasConcept C136264566 @default.
• W3011397103 hasConcept C138816342 @default.
• W3011397103 hasConcept C144133560 @default.
• W3011397103 hasConcept C147859227 @default.
• W3011397103 hasConcept C159110408 @default.
• W3011397103 hasConcept C160735492 @default.
• W3011397103 hasConcept C162324750 @default.
• W3011397103 hasConcept C162853370 @default.
• W3011397103 hasConcept C2780378061 @default.
• W3011397103 hasConcept C2908647359 @default.
• W3011397103 hasConcept C50522688 @default.
• W3011397103 hasConcept C512399662 @default.
• W3011397103 hasConcept C71924100 @default.
• W3011397103 hasConcept C83864248 @default.
• W3011397103 hasConcept C99454951 @default.
• W3011397103 hasConceptScore W3011397103C10138342 @default.
• W3011397103 hasConceptScore W3011397103C104863432 @default.

• next